Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| nadroparinNCT00303407 | University Hospital, GenevaPhase unknown | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2006-03-16 |
| DalteparinNCT00260520 | University of FlorencePhase unknown | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2006-03-06 |
| Tenofovir Disoproxil FumarateNCT00122512 | FHI 360PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-02-10 |
| M40403NCT00101621 | MetaPhore PharmaceuticalsPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-02-09 |
| melatonin 0.5 mgNCT00288262 | Scripps HealthPHASE1, PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-02-07 |
| rituximabNCT00100737 | Chiron CorporationPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-02-06 |
| interleukin-2NCT00100737 | Chiron CorporationPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-02-06 |
| prosaptideNCT00286377 | Savient PharmaceuticalsPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-02-03 |
| CG7870NCT00103428 | Cell GenesysPHASE1, PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-02-02 |
| S-1NCT00209664 | Hokkaido Gastrointestinal Cancer Study GroupPHASE2 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-02-02 |
| irinotecanNCT00209664 | Hokkaido Gastrointestinal Cancer Study GroupPHASE2 | SUSPENDED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-02-02 |
| fluticasone 500 mcg + salmeterol 50 mcgNCT00158847 | Leiden University Medical CenterPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-01-20 |
| fluticasone 500 mcgNCT00158847 | Leiden University Medical CenterPHASE4 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2006-01-20 |
| GonyautoxinNCT00276952 | University of ChilePHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-01-13 |
| activated lymphocytesNCT00151645 | Rennes University HospitalPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2006-01-02 |
| RUPATADINENCT00199251 | J. Uriach and CompanyPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2005-12-23 |
| MitoxantroneNCT00219908 | Rennes University HospitalPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2005-12-22 |
| RiluzoleNCT00211224 | King's College LondonPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2005-12-15 |
| Intraocular pressure reductionNCT00262626 | Dalhousie UniversityNA | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential50 Operational complexity50 Licensing attractivenessUnknown | Registry evidence2005-12-07 |
| DaunorubicineNCT00219765 | Poitiers University HospitalPHASE1, PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2005-11-28 |
| CytarabineNCT00219765 | Poitiers University HospitalPHASE1, PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2005-11-28 |
| Imatinib mesylate 600 mgNCT00219765 | Poitiers University HospitalPHASE1, PHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2005-11-28 |
| CC5013NCT00179738 | Celgene CorporationPHASE2 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2005-11-23 |
| FluoxetineNCT00005015 | National Institute of Mental Health (NIMH)PHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2005-11-21 |
| RG1068 (Synthetic Human Secretin)NCT00036231 | Repligen CorporationPHASE3 | TERMINATED Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2005-11-21 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |